Unlocking nature's arsenal: Nanotechnology for targeted delivery of venom toxins in cancer therapy
Source abstract
Abstract
Aim The aim of the present review is to shed light on the nanotechnological approaches adopted to overcome the shortcomings associated with the delivery of venom peptides which possess inherent anti-cancer properties. Background Venom peptides although have been reported to demonstrate anti-cancer effects, they suffer from several disadvantages such as in vivo instability, off-target adverse effects, limited drug loading and low bioavailability. This review presents a comprehensive compilation of different classes of nanocarriers while underscoring their advantages, disadvantages and potential to carry such peptide molecules for in vivo delivery. It also discusses various nanotechnological aspects such as methods of fabrication, analytical tools to assess these nanoparticulate formulations, modulation of nanocarrier polymer properties to enhance loading capacity, stability and improve their suitability to carry toxic peptide drugs. Conclusion Nanotechnological approaches bear great potential in delivering venom peptide-based molecules as anticancer agents by enhancing their bioavailability, stability, efficacy as well as offering a spatiotemporal delivery approach. However, the challenges associated with toxicity and biocompatibility of nanocarriers must be duly addressed. Perspectives The everlasting quest for new breakthroughs for safer delivery of venom peptides in human subjects is fuelled by unmet clinical needs in the current landscape of chemotherapy. In addition, exhaustive efforts are required in obtaining and purifying the venom peptides followed by designing and optimizing scale up technologies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Healthcare and Venom Research · Venomous Animal Envenomation and Studies · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Tumour suppressor genes in chemotherapeutic drug response10.1042/BSR20110125 ↗
2. Cancer and radiation therapy: current advances and future directions10.7150/ijms.3635 ↗
3. G.C. Barnett, C.M.L. West, A.M. Dunning, R.M. Elliott, C.E. Coles, P.D.P. Pharoah, N.G. Burnet, Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype, Nat. Rev. Cancer 2009 9:2 9 (2009) 134–142. doi:https://doi.org/10.1038/nrc2587.10.1038/nrc2587 ↗
4. Immunotherapy targets in pediatric cancer
5. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches10.1016/j.micpath.2017.11.034 ↗
6. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches10.1016/j.micpath.2017.11.034 ↗
7. Peptide therapeutics from venom: current status and potential10.1016/j.bmc.2017.09.029 ↗
8. Venoms as a platform for human drugs: translating toxins into therapeutics
9. Antitumoural effect of an l-amino acid oxidase isolated from Bothrops jararaca snake venom10.1111/j.1742-7843.2008.00229.x ↗
10. Therapeutic potential of snake venom in cancer therapy: current perspectives10.1016/S2221-1691(13)60042-8 ↗
11. Therapeutic potential of snake venom in cancer therapy: current perspectives10.1016/S2221-1691(13)60042-8 ↗
12. Applications of snake venoms in treatment of cancer10.1016/S2221-1691(15)30344-0 ↗
13. Antitumoral activity of snake venom proteins: new trends in cancer therapy10.1155/2014/203639 ↗
14. Types of snake venom
15. Physicochemical and biological characterization of nanovenoms, a new tool formed by silica nanoparticles and Crotalus durissus terrificus venom10.1016/j.colsurfb.2020.111128 ↗
16. Cytotoxic activity of Crotalus molossus molossus snake venom-loaded in chitosan nanoparticles against T-47D breast carcinoma cells
17. Anticancer potential of nanogold conjugated toxin GNP-NN-32 from Naja naja venom10.1590/1678-9199-jvatitd-2019-0047 ↗
18. Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: molecular targets for cell cycle arrest and apoptosis induction10.1016/j.cellimm.2013.07.016 ↗
19. Snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles induce apoptosis and growth arrest in human prostate cancer cells10.1007/s10495-012-0787-1 ↗
20. Silica nanoparticles sensitize human multiple myeloma cells to snake (Walterinnesia aegyptia) venom-induced apoptosis and growth arrest10.1155/2012/386286 ↗
21. Preparation, characterization, and anticancer activity assessment of chitosan/TPP nanoparticles loaded with Echis carinatus venom10.2174/0118715206279731231129105221 ↗
22. Cellular and molecular mechanisms underlie the anti-tumor activities exerted by Walterinnesia aegyptia venom combined with silica nanoparticles against multiple myeloma cancer cell types10.1371/journal.pone.0051661 ↗
23. Evaluation of cytotoxicity of a purified venom protein from Naja kaouthia (NKCT1) using gold nanoparticles for targeted delivery to cancer cell10.1016/j.cbi.2016.11.007 ↗
24. Emami · 2022 · 2
25. T. Bhowmik, P. Pratim Saha, A. Kumar DasGupta, A. Gomes, Influence of Gold Nanoparticle Tagged Snake Venom Protein Toxin NKCT1 on Ehrlich Ascites Carcinoma (EAC) and EAC Induced Solid Tumor Bearing Male Albino Mice, (n.d.).
26. Antileukemic potential of PEGylated gold nanoparticle conjugated with protein toxin (NKCT1) isolated from Indian cobra (Naja kaouthia) venom10.1007/s12645-013-0036-5 ↗
27. Liposomes containing an ASP49-phospholipase A2 from Bothrops jararacussu snake venom as experimental therapy against cutaneous leishmaniasis10.1016/j.intimp.2016.04.025 ↗
28. Gold nanoparticles (AuNPs) conjugated with Andrographolide ameliorated viper (Daboia russellii russellii) venom-induced toxicities in animal model10.1166/jnn.2020.17421 ↗
29. Liposomes containing alkylated methotrexate analogues for phospholipase A2 mediated tumor targeted drug delivery10.1016/j.chemphyslip.2008.11.005 ↗
30. Formulation, characterization and cellular toxicity assessment of a novel bee-venom microsphere in prostate cancer treatment10.1038/s41598-022-17391-w ↗
31. Cytolytic peptide nanoparticles (’NanoBees’) for cancer therapy10.1002/wnan.126 ↗
32. Therapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer- and prostate cancer-bearing experimental mouse models10.1016/j.freeradbiomed.2013.06.018 ↗
33. Modern trends in animal venom research - omics and nanomaterials10.4331/wjbc.v8.i1.4 ↗
34. Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles10.2217/17435889.3.4.495 ↗
35. The use of α-conotoxin ImI to actualize the targeted delivery of paclitaxel micelles to α7 nAChR-overexpressing breast cancer10.1016/j.biomaterials.2014.11.044 ↗
36. Crosslinking-induced endocytosis of acetylcholine receptors by quantum dots
37. Antileukemic potential of PEGylated gold nanoparticle conjugated with protein toxin (NKCT1) isolated from Indian cobra (Naja kaouthia) venom10.1007/s12645-013-0036-5 ↗
38. Preparation and in vitro anti-tumor properties of toad venom extract-loaded solid lipid nanoparticles
39. Wasp venom peptide improves the proapoptotic activity of alendronate sodium in A549 lung cancer cells10.1371/journal.pone.0264093 ↗
40. Biosynthesis of gold nanoparticles using jellyfish nematocyst venom protein and evaluation of their anticancer activity against breast cancer cells: in-vitro study10.1016/j.cplett.2023.140523 ↗
41. Overview of scorpion toxins specific for Na+ channels and related peptides: biodiversity, structure–function relationships and evolution10.1016/j.toxicon.2005.09.006 ↗
42. Voltage-gated sodium channel modulation by scorpion α-toxins10.1016/j.toxicon.2006.09.023 ↗
43. Emerging options for the management of scorpion stings10.2147/DDDT.S24754 ↗
44. Scorpion venom peptides without disulfide bridges10.1080/15216540500058899 ↗
45. Scorpion venom components as potential candidates for drug development10.1016/j.toxicon.2014.11.233 ↗
46. Scorpion venoms as a potential source of novel cancer therapeutic compounds
47. Modulation of glioma cell migration and invasion using cl− and K+ ion channel blockers10.1523/JNEUROSCI.19-14-05942.1999 ↗
48. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci10.1158/0008-5472.CAN-06-3948 ↗
49. Purification and N-terminal sequence of a serine proteinase-like protein (BMK-CBP) from the venom of the Chinese scorpion (Buthus martensii Karsch)10.1016/j.toxicon.2008.06.003 ↗
50. Isolation and characterization of a hyaluronidase from the venom of Chinese red scorpion Buthus martensi
51. Cell-cycle-dependent expression of the large Ca2+-activated K+ channels in breast cancer cells10.1016/j.bbrc.2004.02.041 ↗
52. Apoptosis induction in human leukemic cells by a novel protein Bengalin, isolated from Indian black scorpion venom: through mitochondrial pathway and inhibition of heat shock proteins10.1016/j.cbi.2009.11.006 ↗
53. A hyaluronidase from Tityus serrulatus scorpion venom: isolation, characterization and inhibition by flavonoids10.1016/S0041-0101(01)00122-2 ↗
54. General sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC10.1371/journal.pone.0039290 ↗
55. Scorpion and spider venoms in cancer treatment: state of the art, challenges, and perspectives
56. Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles10.1002/smll.200800646 ↗
57. Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles10.2217/17435889.3.4.495 ↗
58. Smart chlorotoxin-functionalized liposomes for sunitinib targeted delivery into glioblastoma cells
59. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration10.1016/j.biomaterials.2010.11.079 ↗
60. Iron oxide nanoparticles decorated with functional peptides for a targeted siRNA delivery to glioma cells
61. Boosting curcumin activity against human prostatic cancer PC3 cells by utilizing scorpion venom conjugated phytosomes as promising functionalized nanovesicles10.1080/10717544.2022.2048133 ↗
62. Functionalization of iron oxide magnetic nanoparticles with targeting ligands: their physicochemical properties and in vivo behavior10.2217/nnm.10.55 ↗
63. Colon targeted Eudragit coated beads loaded with optimized fluvastatin-scorpion venom conjugate as a potential approach for colon cancer therapy
64. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery10.1016/j.biomaterials.2010.07.016 ↗
65. Chlorotoxin peptide-functionalized polyethylenimine-entrapped gold nanoparticles for glioma SPECT/CT imaging and radionuclide therapy10.1186/s12951-019-0462-6 ↗
66. Chlorotoxin-conjugated nanoparticles as potential glioma-targeted drugs10.1007/s11060-011-0763-6 ↗
67. Chlorotoxin modified morusin–PLGA nanoparticles for targeted glioblastoma therapy10.1039/C9TB01131E ↗
68. Temozolomide nanoparticles for targeted glioblastoma therapy10.1021/am5092165 ↗
69. Contributions of some biological activities of honey bee venom
70. The bee venom test: a new tonic-pain test10.1016/0304-3959(96)03075-8 ↗
71. Venom-based peptide therapy: insights into anti-cancer mechanism10.18632/oncotarget.21740 ↗
72. Therapeutic properties of bioactive compounds from different honeybee products10.3389/fphar.2017.00412 ↗
73. Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-κB and AP-1-dependent MMP-9 expression10.1007/s10059-010-0028-9 ↗
74. The inhibition of cell growth through the EGFR/ERK/MMP-2 pathway induced by Ampelopsin in the human malignant melanoma A375 cell line
75. The apamin-sensitive Ca2+-dependent K+ channel: molecular properties
76. Determinants of apamin and d-tubocurarine block in SK potassium channels10.1074/jbc.272.37.23195 ↗
77. Apamin inhibits NO-induced relaxation of the spontaneous contractile activity of the myometrium from non-pregnant women10.1186/1477-7827-1-8 ↗
78. Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation10.1016/S0196-9781(98)00167-3 ↗
79. Mast cell degranulating (MCD) peptide: a prototypic peptide in allergy and inflammation10.1016/S0196-9781(98)00167-3 ↗
80. Chemical composition of bee venom10.1007/978-3-319-59689-1_13 ↗
81. M.A. Moga, O.G. Dimienescu, C.A. Arvătescu, P. Ifteni, L.P. Pleş, Molecules Anticancer Activity of Toxins from Bee and Snake Venom-An Overview on Ovarian Cancer, (2018). doi:https://doi.org/10.3390/molecules23030692.10.3390/molecules23030692 ↗
82. Molecular modes of action of cantharidin in tumor cells10.1016/j.bcp.2004.12.003 ↗
83. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio10.1016/j.canlet.2004.07.045 ↗
84. Induction of apoptosis by norcantharidin in human colorectal carcinoma cell lines: involvement of the CD95 receptor/ligand10.1007/s00432-002-0326-5 ↗
85. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio10.1016/j.canlet.2004.07.045 ↗
86. Cantharidin-based small molecules as potential therapeutic agents10.1111/cbdd.12180 ↗
87. Cantharidin induces G2/M phase arrest and apoptosis in human colorectal cancer Colo 205 cells through inhibition of CDK1 activity and caspase-dependent signaling pathways
88. Suppressions of migration and invasion by cantharidin in TSGH-8301 human bladder carcinoma cells through the inhibitions of matrix metalloproteinase-2/-9 signaling
89. Cantharidin and norcantharidin inhibit the ability of MCF-7 cells to adhere to platelets via protein kinase C pathway-dependent downregulation of α2 integrin10.3892/or.2013.2601 ↗
90. Oral bioavailability of cantharidin-loaded solid lipid nanoparticles
91. Key regulators in bee venom-induced apoptosis are Bcl-2 and caspase-3 in human leukemic U937 cells through downregulation of ERK and Akt10.1016/j.intimp.2006.07.027 ↗
92. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway10.1002/hep.22240 ↗
93. Inhibition of COX-2 activity and proinflammatory cytokines (TNF-α and IL-1β) production by water-soluble sub-fractionated parts from bee (Apis mellifera) venom10.1007/BF02976695 ↗
94. X. Yu, L. Chen, J. Liu, B. Dai, G. Xu, G. Shen, Q. Luo, Z. Zhang, Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis, Nat. Commun. 2019 10:1 10 (2019) 1–14. doi:https://doi.org/10.1038/s41467-019-08538-x.10.1038/s41467-019-08538-x ↗
95. X. Yu, Y. Dai, Y. Zhao, S. Qi, L. Liu, L. Lu, Q. Luo, Z. Zhang, Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response, Nat. Commun. 2020 11:1 11 (2020) 1–14. doi:https://doi.org/10.1038/s41467-020-14906-9.10.1038/s41467-020-14906-9 ↗
96. Development of D-melittin polymeric nanoparticles for anti-cancer treatment10.1016/j.biomaterials.2021.121076 ↗
97. Hybrid melittin cytolytic peptide-driven ultrasmall lipid nanoparticles block melanoma growth in vivo10.1021/nn400683s ↗
98. Stable loading and delivery of melittin with lipid-coated polymeric nanoparticles for effective tumor therapy with negligible systemic toxicity10.1021/acsami.1c17618 ↗
99. MnO2-melittin nanoparticles serve as an effective anti-tumor immunotherapy by enhancing systemic immune response10.1016/j.biomaterials.2022.121706 ↗
100. Nanoparticle incorporation of melittin reduces sperm and vaginal epithelium cytotoxicity10.1371/journal.pone.0095411 ↗